Aptevo Therapeutics Q1 EPS $(9.95) Beats $(12.84) Estimate
Portfolio Pulse from Benzinga Newsdesk
Aptevo Therapeutics reported a Q1 EPS loss of $(9.95), surpassing the analyst consensus estimate of $(12.84) by 22.51%. This marks a significant improvement from the previous year's Q1 loss of $(43.12) per share, indicating a 76.92% increase in performance.
May 08, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aptevo Therapeutics reported a smaller than expected Q1 loss of $(9.95) per share, outperforming the consensus estimate of $(12.84) and showing a substantial year-over-year improvement.
Beating EPS estimates typically generates positive investor sentiment, suggesting a potential short-term uptick in APVO's stock price. The significant improvement from last year's performance further strengthens the case for a positive market reaction.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100